Compiled in 2001, Windlas Biotech Ltd is one of the leading companies in the development and manufacturing contract (CDMO) in India. The company offers a wide range of CDMO services from product discovery to product development, licensing, and commercialization of standard products including complex generic.
It also sells its branded products in the genics market and OTC markets. At present, the company is focused on introducing standard medical products to chronic treatment related to lifestyle-related disorders. The business operates in 3 vertical; 1. CDMO products and services, 2. Over-the-counter and over-the-counter (OTC) (nutraceutical and health supplement products) products, and 3. Export.
Leading pharma companies namely Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are other customers of Windlas Biotech market. Its production facilities are located at Dehradun with an installed capacity of 7,063.83 million tablets / tablets, bag / bag, and 61.08 million liquid bottles.
- Leading market player in the domestic pharmaceutical formulation CDMO segment.
- Strong focus on the chronic therapeutic category.
- state-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
- Professional and experienced Promoters and a senior management team.
- An innovative product portfolio of complex generic products.
- Robust financial performance track record.
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the company promoters.
|Particulars||For the year/period ended (₹ in million)|
|Profit After Tax||96.74||162.13||638.22||111.98|
Objects Of The Issue
- To purchase equipment required for capacity expansion of our existing facility at Dehradun Plant IV.
- To finance incremental working capital requirements of the company.
- Repayment/prepayment of company’s borrowings.
- General corporate purposes.
Windlas Biotech IPO – Details
|IPO Opening Date||Aug 04, 2021|
|IPO Closing Date||Aug 06, 2021|
|Issue Type||Book Built Issue IPO|
|Issue Size||401.53 Crore|
|Face Value||₹5 per equity share|
|IPO Price|| To  Per Equity Share|
|Market Lot||30 Shares|
|Min Order Quantity||30 Shares|
|Listing At||BSE NSE|
|Total Share Issue||87,29,023 Equity Share|
|Register||LinkInTime India Private Limited|
Windlas Biotech IPO – Timetable
|IPO Open Date||Aug 04, 2021|
|IPO Close Date||Aug 06, 2021|
|Basis of Allotment Date||Aug 11, 2021|
|Initiation of Refunds||Aug 12, 2021|
|Credit of Shares to Demat Account||Aug 13, 2021|
|IPO Listing Date||Aug 16, 2021|
Windlas Biotech IPO Lots Size & Price
|Application||Lots||Shares||Amount ( Cut-Off)|
Company Contact Information
|Windlas Biotech Limited|
40/1, Mohabewala Industrial Area,
Phone: +91 135 6608000
Windlas Biotech IPO FAQs
|What is Windlas Biotech IPO?|
Windlas Biotech IPO is a main-board IPO of [.] equity shares of the face value of ₹5 aggregating up to ₹[.] Crores. The issue is priced at [.] to [.] per equity share. The minimum order quantity is .
The IPO opens on Aug 4, 2021, and closes on Aug 6, 2021.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
|When Windlas Biotech IPO will open?|
The Windlas Biotech IPO opens on Aug 4, 2021 and closes on Aug 6, 2021.
|What is the lot size of Windlas Biotech IPO?|
Windlas Biotech IPO lot size and the minimum order quantity is not available at this time. Please check again later.
|How to apply for Windlas Biotech IPO?|
You can apply in Windlas Biotech IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services.
|When is Windlas Biotech IPO listing date?|
The Windlas Biotech IPO listing date is announced. The date of Windlas Biotech IPO listing is Aug 16, 2021.